Lilly

Pricing pressures peg back Lilly’s growth products

second entrant Ajovy (fremanezumab) from Teva, according to Lilly,   but still well behind Amgen’s first-to-market Aimovig (erenumab). ... Overall, Lilly is predicting sales of $22bn-$22.5bn for 2019 as a whole, down on its earlier estimate of

Solid Q1 results lift Pfizer as it waits for pipeline boost

Albert Bourla, CEO, Pfizer. Much like Eli Lilly, Pfizer’s first quarter results were a story of volume growth offset by pricing pressures, with a net price decline across the portfolio ... The CDK 4/6 inhibitor looks set to remain one of Pfizer’s

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Lilly says it will present data from the trial at the American Society of Clinical Oncology (ASCO) meeting in June. ... Lilly wants to ensure that patients and physicians feel supported during this important time,” stated Anne White, president, Lilly

Post-merger Celgene to lead pharma growth

Behind Celgene is a cohort of five companies which are expected to post profit growth of 6-10%: AbbVie, AstraZeneca, Eli Lilly, Stada and Takeda.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]